These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 30747416)
1. The Role of Biomarkers in Alzheimer's Disease Drug Development. Cummings J Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416 [TBL] [Abstract][Full Text] [Related]
3. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R; Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606 [TBL] [Abstract][Full Text] [Related]
4. Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease. Penny LK; Lofthouse R; Arastoo M; Porter A; Palliyil S; Harrington CR; Wischik CM Transl Neurodegener; 2024 May; 13(1):25. PubMed ID: 38773569 [TBL] [Abstract][Full Text] [Related]
5. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825 [TBL] [Abstract][Full Text] [Related]
6. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. Dickerson BC; Sperling RA NeuroRx; 2005 Apr; 2(2):348-60. PubMed ID: 15897955 [TBL] [Abstract][Full Text] [Related]
7. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136 [TBL] [Abstract][Full Text] [Related]
8. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. Khan TK; Alkon DL J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622 [TBL] [Abstract][Full Text] [Related]
9. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Cummings J Alzheimers Dement; 2019 Jan; 15(1):172-178. PubMed ID: 29936146 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307 [TBL] [Abstract][Full Text] [Related]
11. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. Cummings J J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950 [TBL] [Abstract][Full Text] [Related]
12. The "rights" of precision drug development for Alzheimer's disease. Cummings J; Feldman HH; Scheltens P Alzheimers Res Ther; 2019 Aug; 11(1):76. PubMed ID: 31470905 [TBL] [Abstract][Full Text] [Related]
13. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force. Cummings J; Fox N; Vellas B; Aisen P; Shan G J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703 [TBL] [Abstract][Full Text] [Related]
20. The development of effective biomarkers for Alzheimer's disease: a review. Henry MS; Passmore AP; Todd S; McGuinness B; Craig D; Johnston JA Int J Geriatr Psychiatry; 2013 Apr; 28(4):331-40. PubMed ID: 22674539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]